PharmAust media thread, page-308

Here is a bit more info from Fight MND NZ. The drug Qalsody
https://mnd.org.nz/wp-content/uploads/2024/04/20240404-MND-NZ-Statement-on-Tofersen-Final-Approved.pdf

Warnings

Qalsody can cause serious side effects, contact your doctor immediately if you have:

Inflammation of the spinal cord (myelitis) and/ or irritation of the nerve roots (radiculitis) can occur in patients treated with Qalsody. Discuss with your healthcare provider to learn about the symptoms associated with myelitis or radiculitis. Treatment with Qalsody may need to be interrupted or discontinued.

Swelling of the optic nerve (papilledema) and increased pressure inside the skull (elevated intracranial pressure ) can occur in patients treated with Qalsody. Discuss with your healthcare provider what the symptoms associated with papilledema or elevated intracranial pressure are.

Inflammation of the brain linings (aseptic meningitis) can occur in patients treated with Qalsody in patients treated with Qalsody. Discuss with your healthcare provider to learn more about symptoms associated with aseptic meningitis.

How is Qalsody administered?

Qalsody is administered intrathecally using a lumbar puncture, this means that it is given as an injection into the spinal canal.

Dosing information

Loading dose: 100 mg intrathecally every 14 days for 3 doses

Maintenance dose: 100 mg intrathecally every 28 days

From here https://www.drugs.com/qalsody.html

Must admit a few tablets sounds more appealing.